Research Letters Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

AIDS

Volumn 22, Issue 18, 2008, Pages 2535-2537

  Rodríguez Nóvoa, Sonia ^a   Morello, Judit ^a   González, Mar ^a   Vispo, Eugenia ^a   Barreiro, Pablo ^a   González Pardo, Gema ^a   Jiménez Nácher, Inmaculada ^a   Gonzalez Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; BILIRUBIN; HEMOGLOBIN; INDINAVIR; LOPINAVIR; NUCLEOSIDE ANALOG; PEGINTERFERON; RIBAVIRIN; RITONAVIR; ZIDOVUDINE; ANTIVIRUS AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE; OLIGOPEPTIDE; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BILIRUBIN METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TRANSPORT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PATIENT COMPLIANCE; PHOSPHORYLATION; PRIORITY JOURNAL; DRUG EFFECT; DRUG INTERACTION; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; BILIRUBIN; DRUG INTERACTIONS; FEMALE; GLUCURONOSYLTRANSFERASE; HEPACIVIRUS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERBILIRUBINEMIA; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RIBAVIRIN;

EID: 57349138829     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283177f38     Document Type: Article

References (14)

1. Rodriguez-Novoa S, Barreiro P, Rendon A, Barrios A, Corral A, Jimenez-Nacher I, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C → T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006;42:291-295.
2. Brierley C, Burchell B. Human UDP-glucuronosyl transferases: chemical defence, jaundice and gene therapy. Bioessays 1993;15:749-754.
3. Soriano V, Barreiro P, Martin-Carbonero L, Vispo E, Garcia- Samaniego J, Labarga P, et al. Update on the treatment of chronic hepatitis C in HIV-infected patients. AIDS Rev 2007;9:99-113.
4. Rockstroh J, Mocroft A, Soriano V, Tural C, Losso M, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192:992-1002.
5. Fried M. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36 (Suppl 1):237-244.
6. Vogt M, Hartshorn K, Furman P, Chou T, Fyfe J, Coleman L, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-1379.
7. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:280-281.
8. Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Martín- Carbonero L, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008;13:429-437.
9. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996;347:578-581.
10. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, Gonzalez- Pardo G, Jimenez-Nacher I, Gonzalez-Lahoz J, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007;21:41-46.
11. Tribut O, Arvieux C, Michelet C, Chapplain JM, Allain H, tue- Ferrer D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two nonnucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. Ther Drug Monit 2002;24:554-562.
12. Morello J, Rodriguez-Novoa S, Cantillano AL, Gonzalez-Pardo G, Jimenez I, Soriano V. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Ther Drug Monit 2007;29:802-806.
13. Jarvis S, Thorn J, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 1998;123:1587-1592.
14. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004.